CoChat

Multiple myeloma: practice patterns across Europe

Raab, Marc S., Cavo, Michele, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Schoen, Paul, Yong, Kwee · 2016 · British Journal of Haematology
Cited by 112

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary: Real‐world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland, UK) observational chart review was conducted to address this. Physicians completed questionnaires for every patient seen during a 2–4‐week observation period, regardless of treatment status. A total of 435 physicians completed 7635 cross‐sectional chart reviews. Overall, 47% of patients were undergoing anti‐tumour drug treatment, 42% had previously received ≥1 line of treatment and 12% had never received anti‐tumour drug treatment. Of the patients treated by oncologists, onco‐haematologists or internists, 95% received, or were expected to receive, at least one line of anti‐tumour drug treatment, 61% received ≥2 lines of therapy and 38% received ≥3 lines. Except in the UK, the most commonly used induction therapies contained bortezomib (48%); lenalidomide was the most commonly used first‐line maintenance therapy (45%) and second‐ and third‐line agent overall (60% and 52% of patients at those lines, respectively). Bortezomib retreatment was used in 47% of patients who received it first line. Treatment patterns became more diverse with subsequent treatment lines. This study provides insight into real‐world treatment patterns in Europe. While treatment practices are broadly similar across countries, some notable differences in the agents used exist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.14193

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×

    “This is perhaps surprising given the activity of bortezomib and lenalidomide in second- and third-line settings (Richardson et al, 2005, 2007; Dimopoulos et al, 2007; Weber et al, 2007) and the availability of bendamustine and pomalidomide for patients refractory to these agents.”
  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 1×

    “This is perhaps surprising given the activity of bortezomib and lenalidomide in second- and third-line settings (Richardson et al, 2005, 2007; Dimopoulos et al, 2007; Weber et al, 2007) and the availability of bendamustine and pomalidomide for patients refractory to these agents.”

Show all 2 references

Cited by

See all 112

Metadata

Authors
Raab, M. S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Schoen, P., & Yong, K.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2016-06-13
Volume
175
Issue
1
Pages
66-76
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2443618845
Cited by
112
References
2
FWCI
9.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple myeloma: practice patterns across Europe. https://app.cochat.ai/papers/10.1111/bjh.14193
The paper
Raab, M. S., Cavo, M., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Schoen, P., & Yong, K. (2016). Multiple myeloma: practice patterns across Europe. British Journal of Haematology. https://doi.org/10.1111/bjh.14193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.